Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
businesswire.com
⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in